Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $664,000.

  • Kymera Therapeutics' Change in Accured Expenses fell 75.85% to $664,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 40.80%. This contributed to the annual value of $4.2 million for FY2024, which is 31.45% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Change in Accured Expenses stood at $664,000, which was down 86.02% from $4.8 million recorded in Q2 2025.
  • Kymera Therapeutics' Change in Accured Expenses' 5-year high stood at $9.0 million during Q4 2024, with a 5-year trough of -$15.4 million in Q1 2024.
  • In the last 3 years, Kymera Therapeutics' Change in Accured Expenses had a median value of $2.7 million in 2024 and averaged $98,636.
  • In the last 5 years, Kymera Therapeutics' Change in Accured Expenses spiked by 642.74% in 2021 and then tumbled by 1,069.36% in 2022.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Change in Accured Expenses stood at $3.8 million in 2021, then declined by 25.13% to $2.8 million in 2022, then skyrocketed by 139.02% to $6.8 million in 2023, then surged by 32.81% to $9.0 million in 2024, then tumbled by 75.85% to $664,000 in 2025.
  • Its Change in Accured Expenses stands at $664,000 for Q3 2025, versus $4.8 million for Q2 2025 and -$11.7 million for Q1 2025.